Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Advanced Urothelial TCC
NCT00072150Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2003
- Primary completion
- Mar 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Response rates (CR+PR) up to 6 years. Started Oct 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00072150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072150.